|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
146,000,000 |
Market
Cap: |
17.97(B) |
Last
Volume: |
1,136,933 |
Avg
Vol: |
1,328,632 |
52
Week Range: |
$92.79 - $212.65 |
|
Level
I Sector: |
Information Technology |
Level
II Sector: |
Electronics |
Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : 11.4 |
Insider 6 Months : 11.4 |
Insider 3/6 Months : 23.2 |
|
Guru Rank Number : 691 |
Guru Rank Value : 2.3 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
7,330 |
7,330 |
7,330 |
7,330 |
Total Buy Value |
$991,672 |
$991,672 |
$991,672 |
$991,672 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
0 |
315 |
6,815 |
22,740 |
Total Sell Value |
$0 |
$35,545 |
$1,357,080 |
$4,648,975 |
Total People Sold |
0 |
1 |
2 |
3 |
Total Sell Transactions |
0 |
1 |
5 |
17 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Goswami Joydeep |
SVP Corp Business Development |
|
2022-02-22 |
4 |
D |
$319.86 |
$486,507 |
D/D |
(1,521) |
6,303 |
|
- |
|
Goswami Joydeep |
SVP Corp Business Development |
|
2022-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,979 |
7,824 |
|
- |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2022-01-12 |
4 |
AS |
$425.00 |
$340,000 |
D/D |
(800) |
39,274 |
|
-41% |
|
Hoyt Aimee L |
SVP, Chief People Officer |
|
2022-01-08 |
4 |
D |
$362.28 |
$41,662 |
D/D |
(115) |
3,208 |
|
- |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2021-12-28 |
4 |
AS |
$387.06 |
$38,706 |
D/D |
(100) |
40,074 |
|
-34% |
|
Dadswell Charles |
SVP & General Counsel |
|
2021-12-22 |
4 |
AS |
$380.29 |
$122,453 |
I/I |
(322) |
3,283 |
|
-21% |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2021-12-08 |
4 |
AS |
$375.00 |
$37,500 |
D/D |
(100) |
40,174 |
|
-8% |
|
Dadswell Charles |
SVP, General Counsel |
|
2021-11-22 |
4 |
AS |
$377.86 |
$118,648 |
I/I |
(314) |
3,605 |
|
-4% |
|
Febbo Phillip G. |
SVP Chief Medical Officer |
|
2021-11-08 |
4 |
AS |
$406.83 |
$406,830 |
D/D |
(1,000) |
3,015 |
|
-13% |
|
Desouza Francis A |
President and CEO |
|
2021-11-05 |
4 |
D |
$408.14 |
$1,470,937 |
D/D |
(3,604) |
69,150 |
|
- |
|
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-11-05 |
4 |
D |
$408.14 |
$77,955 |
D/D |
(191) |
4,488 |
|
- |
|
Samad Samer Abdul |
SVP and CFO |
|
2021-11-05 |
4 |
D |
$408.14 |
$295,085 |
D/D |
(723) |
6,462 |
|
- |
|
Pegels Kevin Carl |
Chief of Global Operations |
|
2021-11-05 |
4 |
D |
$408.14 |
$234,272 |
D/D |
(574) |
4,845 |
|
- |
|
Dadswell Charles |
SVP & General Counsel |
|
2021-11-05 |
4 |
D |
$408.14 |
$301,615 |
I/I |
(739) |
3,919 |
|
- |
|
Hoyt Aimee L |
SVP, Chief People Officer |
|
2021-11-05 |
4 |
D |
$408.14 |
$177,133 |
D/D |
(434) |
3,323 |
|
- |
|
Reeves Kathryne Gambrell |
SVP, Chief Marketing Officer |
|
2021-11-05 |
4 |
D |
$408.14 |
$39,590 |
D/D |
(97) |
2,387 |
|
- |
|
Goswami Joydeep |
SVP Corp Business Development |
|
2021-11-05 |
4 |
D |
$408.14 |
$107,749 |
D/D |
(264) |
3,789 |
|
- |
|
Febbo Phillip G. |
SVP Chief Medical Officer |
|
2021-11-05 |
4 |
D |
$408.14 |
$182,030 |
D/D |
(446) |
4,015 |
|
- |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2021-11-05 |
4 |
D |
$408.14 |
$400,793 |
D/D |
(982) |
40,274 |
|
- |
|
Pegels Kevin Carl |
Chief of Global OperationsOffi |
|
2021-11-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,419 |
|
-22% |
|
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-11-02 |
4 |
AS |
$409.28 |
$1,207,801 |
D/D |
(2,926) |
4,679 |
|
-22% |
|
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-10-26 |
4 |
AS |
$423.00 |
$1,237,698 |
D/D |
(2,926) |
7,605 |
|
-22% |
|
Dadswell Charles |
SVP & General Counsel |
|
2021-10-22 |
4 |
AS |
$411.00 |
$129,054 |
I/I |
(314) |
4,658 |
|
-23% |
|
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-10-19 |
4 |
AS |
$410.42 |
$1,204,972 |
D/D |
(2,926) |
10,531 |
|
-20% |
|
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-10-12 |
4 |
AS |
$407.29 |
$1,197,350 |
D/D |
(2,926) |
13,457 |
|
-22% |
|
3453 Records found
|
|
Page 7 of 139 |
|
|